A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
IDEAYA Biosciences
Telix Pharmaceuticals (Innovations) Pty Limited
CHU de Quebec-Universite Laval
Hoffmann-La Roche
University Health Network, Toronto
Verity Pharmaceuticals Inc.
Orano Med LLC
Chang Gung Memorial Hospital
Pfizer
Daiichi Sankyo
S. Andrea Hospital
Lahore General Hospital
OncoNano Medicine, Inc.
Calico Life Sciences LLC
St. Olavs Hospital
Centre Hospitalier Universitaire de la Guadeloupe
Novartis
M.D. Anderson Cancer Center
Aarhus University Hospital
Shanghai University of Traditional Chinese Medicine
Arsenal Biosciences, Inc.
University College, London
National Taiwan University Hospital
The Greater Poland Cancer Centre
AIO-Studien-gGmbH
Stanford University
Children's National Research Institute
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Bristol-Myers Squibb
Dana-Farber Cancer Institute
Altor BioScience
M.D. Anderson Cancer Center
Aurigene Discovery Technologies Limited
Queen's University
Charite University, Berlin, Germany
Leap Therapeutics, Inc.
Vitadx
City of Hope Medical Center
Endocyte
H. Lee Moffitt Cancer Center and Research Institute
Turku University Hospital
Medical University of Vienna
Ankara Training and Research Hospital
Nektar Therapeutics
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
University Hospitals Bristol and Weston NHS Foundation Trust
Shanghai Pudong Hospital
Lumos Pharma
Mansoura University
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano